Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBC1501 in Neovascular Age-Related Macular Degeneration
NCT05803785Phase 1Recruiting
- Sponsor
- Benobio Co., Ltd.
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BBC-1501 in age-related macular degeneration (AMD) (3 arms), sponsored by Benobio Co., Ltd. Primary endpoint: Treatment-Emergent Adverse Events at 12 weeks. Started Jul 2025; status: recruiting.
02
Drugs
BBC-1501
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT05803785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05803785.